HealthRX vs MEDVi: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher & Publisher

Reviewed & updated August 14, 2026 · Cites primary sources (FDA, NEJM, CMS) · Not medical advice

54 providers verified independently·Independent research·How we rank →

Short answer: MEDVi scores higher on our rubric, 5.7/10 against 5.2/10. Full reasoning, pricing and the cases where the other one wins are below.

Visit MEDVi - our pick of these two →or find your match

MEDVi beats HealthRX overall, scoring 5.7/10 vs 5.2/10. Published pricing is not a like-for-like monthly comparison: HealthRX is from $99/mo; MEDVi is $179 first month, then $299/mo. Choose HealthRX for cash-pay patients who want low flat-dose compounded glp-1 pricing, all-50-state access, fast shipping, and self-service cancellation. Choose MEDVi for users who want both oral and injectable compounded options in one telehealth program.

A side-by-side look at HealthRX and MEDVi to help you decide. We compare them on:

•Starting price per month
•Our overall score, out of 10
•Medication type, brand-name or compounded
•Whether they accept insurance
•Who each one is best for

HealthRX

#49 of 54

5.2/10

HealthRX is a cash-pay telehealth platform for compounded injectable semaglutide and tirzepatide. Its July 2026 landing page lists semaglutide at $133/mo on a 3-month plan or $99/mo on a 12-month plan, plus tirzepatide at $209/mo or $179/mo. Prices stay flat across doses and include clinician review, dose adjustments, and overnight shipping. MD Integrations supplies the clinician network, while the dispensing 503A pharmacy remains unnamed on the public site.

Visit HealthRX

Higher Rated

MEDVi

#45 of 54

5.7/10

MEDVi offers oral and injectable compounded GLP-1 care. Semaglutide is $179 for month one and $299 for refills. Trustpilot is 4.4/5 across roughly 11,000 reviews, while BBB is F/not accredited. FDA warning letter #721455 concerns misleading labeling and marketing, not an allegation that the medication was unsafe.

Visit MEDVi

Feature	HealthRX	MEDVi
Why each one	Low flat-dose pricing paired with linked LegitScript verification, nationwide clinician coverage, overnight shipping, and self-service account cancellation.	Oral and injectable compounded formats in one program, with micro-dosing options and a path to FDA-approved brand medication.
Our Score	5.2/10	5.7/10
Headline Price	from $99/mo	$179 first month, then $299/mo
Medication Type	Compounded	Both
Insurance Accepted	No	No
Best For	Cash-pay patients who want low flat-dose compounded GLP-1 pricing, all-50-state access, fast shipping, and self-service cancellation	Users who want both oral and injectable compounded options in one telehealth program
Watch out for	The dispensing 503A pharmacy is described by type while its name and license remain absent from the public site	FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication
Ranking	#49	#45
Get started	Visit HealthRX	Visit MEDVi

Pros & Cons Compared

HealthRX

Pros

+$99/mo compounded semaglutide on the 12-month plan, with a $133/mo 3-month option
+Flat pricing across doses, clinician review, dose adjustments, and overnight shipping included
+Licensed clinicians in all 50 states through MD Integrations, with most files reviewed within about 24 hours
+LegitScript certificate 50087439 links to the issuer's verification checker
+Single-click account cancellation and refunds for unshipped doses
+Published HIPAA notice, telehealth consent, safety information, and emergency instructions

Cons

−The dispensing 503A pharmacy is described by type while its name and license remain absent from the public site
−Legal entity, headquarters, executive team, and medical director remain undisclosed
−The tirzepatide product page advertises $149/mo while the current affiliate landing and FAQ say $179/mo, so confirm the checkout rate
−The 4.8/5 from 12,000+ members block uses illustrative composites rather than an independent review platform
−Cash-pay only, with no insurance billing or prior-authorization support
−Compounded medications sit outside FDA premarket approval as finished products

MEDVi

Pros

+One of the few compounded providers offering both oral tablets and injectable semaglutide
+Micro-dosing options available, can start at sub-standard doses for patients concerned about side effects
+Sleek onboarding experience with clear progress tracking through their patient portal
+$179 covers the first month of compounded semaglutide on the current Katalys landing, including clinician review, medication and shipping

Cons

−FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication
−Its third-party records conflict: 4.4/5 across roughly 11,000 Trustpilot reviews, but an F and no accreditation at the BBB
−The $179 semaglutide price is introductory; the current Katalys landing says refills are $299/mo, making the first-year total $3,468 rather than $2,148
−Brand-name Wegovy and Zepbound paths add a $99 membership plus the medication cost, which the current landing does not publish; availability can change
−No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms

Our Verdict

MEDVi edges out HealthRX with a score of 5.7/10 vs 5.2/10. Published pricing is not a like-for-like monthly comparison: HealthRX is from $99/mo; MEDVi is $179 first month, then $299/mo. MEDVi offers both brand-name and compounded medications, giving you more flexibility.